Turkey tail (PSK)
Also called: PSK, Krestin, polysaccharide-K, Coriolus versicolor, Trametes versicolor.
Chapter 18 of The Cancer Evidence Handbook, Part Four. Last reviewed 2026-09-16. How this works.
Adjunct in gastrointestinal cancer Grade C
Human evidence exists and does not settle it.
Licensed in Japan, it showed a small five-year survival benefit, at low certainty, in trials that used older chemotherapy.
Approved in Japan, with a small five-year survival benefit at low certainty.
How this grade was reached
The claim
The claim is that an extract of turkey tail mushroom, given alongside chemotherapy after surgery, improves survival in bowel and stomach cancer.
What it does
PSK is a protein-bound polysaccharide proposed to act on the immune system rather than on the tumour directly.1
The evidence
The trial volume is larger than most entries in this book. A network meta-analysis covering 23 randomised trials and 10,684 patients reported increased one to five year overall survival and one to seven year disease-free survival, with no increase in side effects. It is approved in Japan as an adjuvant therapy.21
Against that, the National Cancer Institute states there is little evidence that turkey tail extracts or PSK are useful for any condition.3
A Cochrane review of seven randomised trials, six of them in Japan, found low-certainty evidence of a small improvement in overall survival at five years, a risk ratio of 1.08, and only very low-certainty evidence on side effects. The chemotherapy used in those trials no longer reflects current practice, so the survival finding describes an older standard of care.4
This is the third time the same shape appears in one chapter, and the book names it: high trial volume from one region, mostly decades old, consistently favourable, and never independently confirmed by anyone without a stake in the answer. It is not approved outside Japan.21
The studies this rests on
-
Network meta-analysis of PSK in gastrointestinal cancer2
A meta-analysis, summarising randomised trials, measured survival, 10684 participants.
increased one to five year overall survival and one to seven year disease-free survival, with no increase in side effects.
What has not been shown
No trial from outside the region where these studies originate has confirmed the finding. The Cochrane review rated the survival evidence low certainty and the side-effect evidence very low certainty.
This applies to: outside the region of origin.
Established by published review, A Cochrane review, CD012053, as recorded in chapter 18 note 6, checked 2026-09-23. Result: seven randomised trials, six from Japan and one from China; a small five-year survival benefit at low certainty, side-effect evidence at very low certainty.4
What to ask
Is there a reason a drug approved in one country has not been approved here?
When to call your team, and what to tell them
Whatever you are taking or thinking of taking, the people treating you can only weigh it if they know about it. That is true when nothing has been written down here, and it is most true then.
The register records no warning signs for PSK. That is not a statement that nothing can go wrong.
Find a trial instead
The unanswered question is what happens when someone outside the region of origin runs the trial.
Search ClinicalTrials.gov for recruiting studies of polysaccharide K OR Trametes versicolor
A trial is the same decision with monitoring, a known preparation and a doctor who knows what else you are taking.
Also recorded for this entry
Does it reach the body?
The register holds no human pharmacokinetic measurement for PSK against any laboratory concentration. What that question means, for every compound here.
Does it clash with a cancer treatment?
The register holds no measured interaction between PSK and a cancer treatment class. An empty list means nobody has measured it. Nobody having looked is not the same as nothing being there.
Every recorded interaction, and how to turn it into a request for your pharmacist.
References
Description of polysaccharide-K, also called Krestin or PSK, a protein-bound polysaccharide isolated from the mycelium of Trametes versicolor, approved in Japan as an adjuvant therapy and not approved in the United States.
No persistent identifier recorded.
How this was reached: taken from the book's notes, chapter 18, note 4.
Ma Y, Wu X, Yu J, Zhu J, Pen X, Meng X. Can polysaccharide K improve therapeutic efficacy and safety in gastrointestinal cancer? A systematic review and network meta-analysis. Oncotarget 2017.
How this was reached: taken from the book's notes, chapter 18, note 5.
National Cancer Institute PDQ summary assessment of turkey tail and PSK.
No persistent identifier recorded.
How this was reached: taken from the book's notes, chapter 18, note 6.
Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer. Cochrane Database of Systematic Reviews CD012053.
doi:10.1002/14651858.CD012053.pub2 · PubMed 36445793 · PMC9707730 · Cochrane CD012053
How this was reached: taken from the book's notes, chapter 18, note 6.